Roche Holding dividend track record and Goldman target, shares under broad analyst scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:15.

Roche Holding AG (CH0012032048) stands out on the SIX Swiss Exchange as one of the largest healthcare names in the SMI, backed by a long series of dividend increases and steady earnings guidance from its latest annual report.

Goldman Sachs nudges Roche target

On June 30, 2026, Goldman Sachs lifted its 12-month price target for Roche shares from 346 to 348 Swiss francs while reiterating a Neutral rating, citing that the group remains on track toward its full-year goals and highlighting the upcoming market launch of the breast cancer drug giredestrant as a key focus for investors. Goldman Sachs note on Roche's price target and rating

Goldman Sachs positions Roche among the global large-cap pharma names where the near-term upside is balanced by execution risks in the pipeline, a stance that explains the Neutral rating despite the modest price-target increase and underscores that the share remains firmly on the radar of international research desks. Bitget overview of analyst targets for Roche Holding

Analyst consensus and institutional interest

Data aggregators summarizing the broader analyst consensus for the London-traded Roche Holding line (ticker 0QOK) show a median 12-month price target of 481 Swiss francs as of June 30, 2026, with estimates ranging from 256.54 to 654.29 francs, based on input from 48 analysts over the past three months and an overall rating distribution of roughly one third Buy, one quarter Hold and just over 40 percent Sell. Analyst target and rating distribution for Roche Holding

Institutional ownership data for Roche's U.S.-traded ADR (RHHBY) show that 77 institutional investors and hedge funds held the stock over the past two years, with 39 institutional buyers and 29 sellers in the last 12 months, and net inflows and outflows both in the mid-20 million dollar range, indicating a broadly held but actively traded position among professional investors. MarketBeat data on Roche ADR institutional holdings

Dividend record and earnings guidance

In its ad hoc announcement on January 29, 2026 covering full-year 2025, Roche reported group sales growth of 7 percent at constant exchange rates, corresponding to 2 percent growth in Swiss francs, underpinned by demand for both medicines and diagnostic solutions, and proposed increasing the dividend to 9.80 francs per share and non-voting equity security, marking the 39th consecutive annual dividend increase if approved by shareholders. Roche 2025 results and dividend proposal press release

For the current year 2026, Roche guided to mid-single-digit group sales growth at constant exchange rates and high-single-digit development of core earnings per share, while stating that it expects to further raise its dividend in Swiss francs, a combination that keeps the stock in focus for income-oriented investors and funds tracking dividend strategies in global healthcare. Roche outlook for 2026 sales and earnings

Role in the Swiss SMI and global healthcare

Roche Holding AG is part of the Swiss Market Index, where it counts among the biggest constituents by market capitalization and influences the performance of a wide range of passive products and index funds that track the benchmark, making the shares a key reference point for investors exposed to the Swiss equity market.

As a healthcare heavyweight, Roche sits alongside peers such as Novartis and international rivals like Pfizer and Merck in global sector indices and exchange-traded funds, with its mix of oncology, immunology and diagnostics businesses providing diversified exposure to pharmaceutical innovation and routine testing volumes.

What the company sells

Roche generates revenue through a broad portfolio of prescription medicines and diagnostic systems, with oncology therapies such as giredestrant and established cancer drugs, combined with next-generation sequencing platforms like AXELIOS 1 and at-home treatment options including Enspryng in selected indications, forming key commercial pillars.

Where the stock trades today

Roche Holding AG shares trade primarily on the SIX Swiss Exchange in Swiss francs and are also represented via ADRs in the United States; a precisely dated intraday price could not be confirmed here, so investors should consult live exchange data for the latest quote.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.